Dietary behaviors in psoriasis: patient-reported outcomes from a U.S
About this article Cite this article Jumadi, J., Ibrahim, I.N., Kadirgama, K
CJC-1295 with DAC Side Effects & Safety Phase 1 data described CJC-1295 with DAC as relatively well tolerated at lower dose ranges, with adverse events increasing at higher exposure
Check your confirmation Youll receive an email with your interview time and instructions for joining the call

Disclosures: Dimple Desai: Nothing to Disclose, Rashmee Patil: Akero Therapeutics: Grant/Research Support, Altimmune: Grant/Research Support, 89Bio: Grant/Research Support, Boehringer Ingelheim: Grant/Research Support, Boston Pharmaceuticals: Grant/Research Support, Eli Lilly: Grant/Research Support, Helio Health: Grant/Research Support, Inventiva: Grant/Research Support, Madrigal Pharmaceuticals: Grant/Research Support, Madrigal Pharmaceuticals: Speaking and Teaching, Merck: Grant/Research Support, Novo Nordisk: Grant/Research Support, Novo Nordisk: Consultant, Galectin Therapeutics: Grant/Research Support, Hepion Pharmaceuticals: Grant/Research Support, GlaxoSmithKline: Grant/Research Support, Corcept Therapeutics: Grant/Research Support 1067 THE EFFECT OF DIET COMPOSITION EXPOSOME ON THE NATURAL HISTORY OF METABOLIC-ASSOCIATED STEATOTIC LIVER DISEASE IN THE MILLION VETERAN PROGRAM COHORT Lauren Callans 1 David Kaplan 2 Kerry Ivey 3 Kyong-Mi Chang 4 , 1 Perelman School of Medicine, University of Pennsylvania, 2 Perelman School of Medicine, 3 Harvard Medical School, 4 Corporal Michael J

& Gersons, B